Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

In the Dog House: Hoffman-La Roche

January 2003

In the Dog House: Hoffman-La Roche Hoffmann-La Roche, maker of saquinavir (Invirase and Fortovase) and ddC (HIVID) for setting the price of their new drug for hepatitis C, called Pegasys, even higher than that charged by Schering Plough for a similar drug.

Schering's price, at around $14,000 per year, was already so high that most people considered it immoral, but despite the impending crisis in funding for drugs, Roche topped them, charging nearly $15,000. Pegasys must be used in combination with a second drug, ribavirin, so the true price is higher still.

Want to tell them how you feel about this? Write or email:
George Abercrombie
President & CEO
Hoffmann-La Roche
340 Kingsland St.
Building 85, 8th Floor
Nutley, NJ 07110
george.abercrombie@roche.com

Advertisement

Back to the Project Inform Perspective January 2003 contents page.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. Visit Project Inform's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement